Menu Search
Equities

Omeros Corp

OMER:NMQ

Omeros Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.26
  • Today's Change-0.03 / -0.70%
  • Shares traded303.01k
  • 1 Year change+240.80%
  • Beta1.4887
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy1
Outperform0
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Omeros Corp share price to rise to 43.00 in the next year from the last price of 4.29.
High902.3%43.00
Med902.3%43.00
Low902.3%43.00

Earnings history & estimates in USD

On Aug 07, 2024, Omeros Corp reported 2nd quarter 2024 losses of -0.97 per share. This result exceeded the -1.14 consensus loss of the 3 analysts covering the company and under-performed last year's 2nd quarter results by 64.41%.
The next earnings announcement is expected on Nov 13, 2024.
Average growth rate-75.17%
Omeros Corp reported annual 2023 losses of -1.88 per share on Apr 01, 2024.
Average growth rate-7.60%
More ▼

Revenue history & estimates in USD

Omeros Corporation did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Omeros Corporation did not report revenues for the full year 2023. However, during the prior year the company reported revenues of 0.00.
Average growth rate-20.64%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.